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SUMMARY
Wnt signalling and the signal transducer and activator of transcription 3 (STAT3)
are oncogenic signalling pathways which are deregulated in colorectal cancer (CRC).
Here we investigated the interaction of these two pathways. Firstly, we investigated
biochemical interaction by inhibiting STAT3 and b-catenin (through gene knock-
down and dominant-negative TCF4 expression) in nine CRC cell lines. b-catenin
inhibition did not affect STAT3 levels, whereas STAT3 knock-down resulted in
reduced b-catenin mRNA and protein levels. The reduction in b-catenin protein was
not prevented by proteasome inhibition, and IL6-induced STAT3 activation resulted
in increased b-catenin mRNA. This suggests that STAT3 positively regulates b-cate-
nin (at a transcriptional level) and evaluation of 44 CRCs by immunostaining sup-
ported this by showing an association between nuclear STAT3 expression and
nuclear b-catenin (P = 0.022). We tested the functional interaction between STAT3
and Wnt signalling by knocking down STAT3 and b-catenin individually and in
combination. Knock-down of b-catenin and STAT3 individually inhibited cell prolif-
eration (P < 0. 001 for each) through G1 arrest. However, simultaneous knock-
down of STAT3 and b-catenin had a significantly weaker effect than knock-down of
b-catenin alone (P < 0.01). Knock-down of STAT3 and b-catenin, individually and
together, inhibited cell motility (P < 0.001) without evidence of interaction. We con-
clude that STAT3 regulates b-catenin but b-catenin does not regulate STAT3. The
STAT3/b-catenin interaction is complex but may reduce the proliferative activity of
b-catenin possibly by taking b-catenin protein beyond the optimal level. This may
indicate biological differences in tumours where both STAT3 and b-catenin are acti-
vated compared to those where only one is activated.
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Introduction
Colorectal cancer (CRC) represents one of the most com-
mon causes of cancer-related death around the world (Stew-
art & Kleihues 2003). The development of CRC is a
paradigm of multistep carcinogenesis with tumours arising
from normal epithelium as a consequence of the stepwise
accumulation of mutations (Ilyas et al. 1999). The ‘order’ of
mutation [first described in the Fearon and Vogelstein model
(Fearon & Vogelstein 1990)] is generally well conserved
allowing mutations to be categorized as ‘early’ or ‘late’
events. The selection of mutations is driven by Darwinian
evolution with mutations which confer a selective advantage
allowing clonal expansion to occur (Greaves & Maley
2012). However, a new mutation will interact with the ante-
cedent mutations, and there may be functional overlap
between different mutations. It is possible therefore that
some mutations may become redundant due to either a
functional redundancy with subsequent mutations or a
change in growth restraints (known as ‘oncogene amnesia’).
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Conversely, some mutations – even if acquired early in the
carcinogenetic process – may remain essential for tumour
cell viability (known as ‘oncogene addiction’) (Felsher
2008).
The earliest event in the development of CRC is probably
activation of the canonical Wnt signalling pathway. In
around 80–90% of cases (Rowan et al. 2000), this occurs
through loss-of-function mutation of the APC gene which
results in failure of the b-catenin destruction complex and
abnormal accumulation of b-catenin protein. Less frequently
mutations in the b-catenin gene (CTNNB1) occur which
result in a degradation-resistant but transcriptionally active
protein (Ilyas et al. 1997). A variety of downstream targets
of b-catenin protein (such as c-Myc, c-Jun, MMP7, Survivin)
are activated and lead to tumour initiation (Wilson et al.
1997; He et al. 1998; Mann et al. 1999; Tetsu & McCor-
mick 1999; Zhang et al. 2001; Conacci-Sorrell et al. 2002).
The signal transducer and activator of transcription 3
(STAT3) pathway is found to be activated in around 50–
60% of CRCs (Morikawa et al. 2011). In contrast to Wnt
signalling, however, activation of this pathway is usually
considered a late event (Kusaba et al. 2005). Activation of
STAT3 occurs following ligand binding to a variety of mem-
branous receptors including receptors for cytokines, hor-
mones and growth factors. However, various intracellular
kinases (such as the src family kinases) can activate STAT3
without receptor involvement (Turkson et al. 1998; Brom-
berg et al. 1999; Simon et al. 2000). Activated STAT3 is
usually phosphorylated on Tyrosine 705 (Bromberg et al.
1999) and, in this form, it translocates to the nucleus where
it can act as a transcription factor. Amongst its targets are
molecules involved in cell proliferation [such as Cyclin D1
and C-Myc (Yu et al. 2009)], apoptosis [such as BCL-2 and
BCL-X (Yu et al. 2009)] and cell motility [such as TWIST
(Cheng et al. 2008)].
Wnt and STAT3 signalling are activated at opposite ends
of the adenoma–carcinoma sequence. That is to say that
deregulation of Wnt signalling is thought to be the first step
in the conversion of normal tissue to adenoma. In contrast,
deregulation of STAT3 is thought to occur in late stage ade-
nomas or invasive carcinomas (Kusaba et al. 2005). Given
the difference in the timing of activation, it is probable that
Wnt and STAT3 signalling confer different selective advan-
tages to tumour cells. There is a degree of overlap in the
reported downstream targets activated by Wnt signalling
and STAT3 signalling. In addition, there is evidence that
STAT3 and b-catenin may influence each other. Thus, in
breast cancer, it has been reported that STAT3 upregulates
the expression and function of b-catenin (Armanious et al.
2010) whilst in oesophageal and some haematological
malignancies, b-catenin appears to upregulate the expression
of STAT3 (Yan et al. 2008; Anand et al. 2010). In CRCs,
published studies have generally examined the effect of
STAT3 on b-catenin with one study claiming that STAT3
caused nuclear localization and increased transcriptional
activity of b-catenin (Kawada et al. 2006). Another study
reported that abrogation of STAT3 signalling causes uncou-
pling of b-catenin from E-Cadherin at the cell–cell junctions
(thereby inducing cell motility), but it has no effect on tran-
scriptional activity of b-catenin (Rivat et al. 2004).
In this study, we sought to elucidate the interactions of
STAT3 and b-catenin at both the biochemical level and the
biological level in CRC. Each gene was knocked down in
several CRC cell lines, and the effects of this on the expres-
sion of the other gene and on the proliferation and motility
of tumour cells were tested.
Materials and methods
Tissue culture
The human CRC cell lines SW620, SW480, HT29,
HCT116, SW837 and SW948 were originally obtained from
the American Type Culture Collection (ATCC). The human
CRC cell lines SW1222, HT55 and C106 were originally
obtained from the European Collection of Cell Cultures
(ECACC). These cell lines were a kind gift from Prof Ian
Tomlinson (Molecular and Population Genetics Laboratory,
London Research Institute, Cancer Research UK, London).
The identity of the cell lines was confirmed prior to com-
mencing the work by mutation profiling as previously
described (Fadhil et al. 2010). Cells were grown in Dul-
becco’s modified Eagle’s medium (DMEM; Invitrogen Cell
Culture, Paisley, UK) supplemented with 10% fetal bovine
serum (FBS; Gibco Invitrogen Cell Culture, Paisley, UK),
100 U/ml penicillin and 100 lg/ml streptomycin and main-
tained at 37°C and 5% CO2 in a humidified incubator.
Cell transfection
STAT3 and b-catenin were knocked down using small inter-
fering RNA (siRNA) as previously described (Albasri et al.
2011). For the knock-down of both, prevalidated Stealth
siRNA duplexes (Invitrogen) were transfected into the cells.
Two different duplexes were used for STAT3, and one was
used for b-catenin; control cells were transfected with siR-
NA targeted to luciferase (sequences for all duplexes are
given in Table S1). Cells were transfected at 30–50% conflu-
ence using lipofectamine 2000 (Invitrogen) to give a final
siRNA concentration of 33 nM and were harvested 48 h
after transfection. As an alternative to knock-down of b-
catenin, inhibition of Wnt signalling was also undertaken by
forced transfection of cells with dominant-negative TCF4
(DN-TCF4) protein. The DN-TCF4 protein expressed by the
plasmid prevents b-catenin from binding to the promoter
regions of b-catenin target genes and therefore prevents b-
catenin-mediated transcriptional activation (Morin et al.
1997). The cell lines HCT116 and HT29 were transfected
with DN-TCF4 expression vector (or empty vector controls)
using lipofectamine 2000 as previously described (Ahmed
et al. 2010), and levels of STAT3 protein were tested 72 h
after transfection.
For experiments investigating the biological interaction of
STAT3 and b-catenin, both genes were silenced indepen-
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dently and together in SW620 cells. For concomitant knock-
down, each duplex was added at 33 nM making a final
siRNA duplex concentration of 66 nM. In these experi-
ments, the final duplex concentration was kept identical and
thus, in conditions where only one of the genes was knocked
down, the final 66 nM concentration was achieved by cor-
rection with luciferase specific siRNA.
Quantitative Reverse Transcription PCR
Quantitative Reverse Transcription PCR (Q-RT-PCR) was
carried out to quantify mRNA of both STAT3 and b-
catenin. Total RNA was extracted from the cells using
the RNeasy Mini Kit (Qiagen, Manchester, UK) following
the manufacturer’s protocol. cDNA was prepared with the
SuperScript III Reverse Transcriptase kit (Invitrogen, Paisley,
UK). PCR was performed in a total volume of 25 ll consist-
ing of 1X Brilliant SYBR Green QPCR Master Mix (Strata-
gene, Cambridge, UK), primers (forward and reverse) at a
final concentration of 250 nM, 30 nM ROX (reference dye)
and 10 ng of the cDNA template. Samples were tested in
triplicate, and no template control and non-reverse tran-
scribed mRNA was included to detect any cDNA or DNA
contamination. PCR was performed on an MX3005P QPCR
machine (Stratagene) using single thermal cycling profile of
(95°C/10 min) X1; [(95°C/30 s)/(56°C/1 min)/(72°C/1 min)]
X40; (72°C/10 min) X1. Quantification was by the standard
curve method using MX3005P QPCR System Software
version 4.01, and data were normalized to the HPRT house-
keeping gene. The sequence of each primer pair and their
products size are detailed in Table S2.
Western blotting
Whole cell extracts were prepared using commercially avail-
able RIPA lysis buffer [20 mM Tris, pH 7.5, 150 mM
NaCl, 1% TritonX-100, 0.5% sodium deoxycholate, 1 mM
EDTA, 0.1% SDS, supplemented with protease and phos-
phatase inhibitors (Sigma, Gillingham, UK)]. Protein (40 lg
in total) was loaded on a 10% SDS–PAGE gel and trans-
ferred on to PVDF membranes (Amersham Bioscience, Buck-
inghamshire, UK) by semidry transfer. After blocking for
1 h with 5% (w/v) milk powder dissolved in 0.1% TPBS
(Tween 20 in Phophate Buffered Saline solution, Sigma),
membranes were incubated overnight at room temperature
with the indicated primary antibody. Antibodies and their
dilutions were anti- b-actin (Sigma-Aldrich) at 1/2000 dilu-
tion, anti STAT3 (Abcam ab50761) at 1/100, anti- c-Myc
(clone 9E10; Abcam, Cambridge, UK) at 1/500, anti-b-cate-
nin (ALX-804-060-C100; Enzo Life Sciences, Exeter, UK) at
1/500. After three 10-min washes in 0.1% TPBS, mem-
branes were incubated for 1 h at room temperature with the
appropriate horseradish peroxidase-linked secondary anti-
body. Following three further washes, detection of bound
antibody was performed using the enhanced chemilumines-
cence kit (Pierce, Rockford, IL, USA). Bands were visualized
using X-ray films (Kodak, Hemel Hempstead, UK).
Proteasome inhibition
To ascertain the role of proteasomal degradation in the
STAT3-mediated regulation of b-catenin, the proteasome
inhibitor Z-Leu-Leu-Phe-CHO (Sigma-Aldrich) dissolved in
DMSO was added to SW620 cells at a final concentration
of 2 lM. Cells were exposed to the proteasomal inhibitor
24 h after transfection with siRNA duplexes. To confirm
the effectiveness of the proteasome inhibition (i.e. a positive
control), the CRC cell line RKO was treated with the pro-
teasome inhibitor and compared with control cells treated
with an equivalent volume of DMSO carrier. The RKO cell
line has an intact b-catenin degradation system making b-
catenin undetectable by Western blot (da Costa et al. 1999).
However, successful inhibition of proteasome activity results
in b-catenin becoming detectable.
Stimulation of the STAT3 pathway
Interleukin-6 can be used to stimulate STAT3 expression
and activity (Yang & Stark 2008). Human recombinant IL-
6 (Immunotools) was used to stimulate the STAT3 signalling
pathway in SW620. Cell lines were stimulated with IL-6 at
a concentration of 20 ng/ml for 12 h. RNA was extracted at
the end of the incubation, and the effect of STAT3 stimula-
tion was determined by Q-RT-PCR.
Tumour sample collection and immunostaining
Local approval for tissue access and study was granted by
the Nottingham Research Biobank (REC reference 05/
Q1605/66). A total of 44 anonymized cases of sporadic
CRC who underwent surgery between 2004 and 2005 were
selected from the archives of the Nottingham University
Hospitals Department of Histopathology. One tumour block
from each case was selected, and a tissue microarray (TMA)
was constructed as previously described (Ullenhag et al.
2007). For immunostaining, 4 lm-thick TMA sections were
dewaxed with xylene, rehydrated through graded alcohol
and then boiled in sodium citrate buffer (0.01 M, pH6) for
10 min for antigen retrieval. Endogenous peroxidase activity
was blocked by immersion in a solution of 0.3% hydrogen
peroxide (in water) for 15 min. Immunostaining was per-
formed using the Dako REALTM kit, and all steps were per-
formed at room temperature. Sections were incubated for
1 h with primary mouse monoclonal antibody diluted in
Dako REALTM diluent buffer (STAT3 (ab50761; Abcam) at
1/20 dilution, b-catenin (M3539; Dako) at 1/200 dilution).
Diluent buffer alone without the primary antibody served as
a negative control. Bound antibody was detected using 3, 30-
Diaminobenzidine tetrahydrochloride as the chromogen
(diluted 1:50 in Dako REALTM HRP buffer) for 10 min.
Sections were counterstained with haematoxylin. The immu-
nostaining was evaluated separately by MI and SI, discrep-
ant cases (where the score varied by more than 10%) were
reviewed together, and a consensus score was reached. Cyto-
plasmic and membranous staining was evaluated using the
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well-described H-score system (Walker 2006), whilst nuclear
staining was scored simply as percentage of tumour nuclei
showing positive staining.
Cell proliferation and apoptosis
The effect of gene silencing on cell number was evaluated at
different time points by the methylene blue assay as previ-
ously described (Dvory-Sobol et al. 2007). Briefly, 48 h fol-
lowing transfection, cells were trypsinized, each well of a six
well plate (Costar) was seeded with 5 9 104 cells and the
number of viable cells, and apoptotic bodies were measured
at specific time points of 24, 48 and 72 h. Apoptosis was
measured by manually counting trypan blue positive cells in
the overall cell population. Cells were trypsinized 72 h after
transfection, resuspended in serum free medium, stained
with trypan blue and counted under the microscope using
haemocytometer. The percentage of apoptotic cells was cal-
culated as the stained cells (i.e. apoptotic cells) divided by
the total. Each experiment was performed in triplicate and
repeated on at least three separate occasions.
Cell cycle analysis
The effect of gene silencing on the cell cycle was evaluated
by flow cytometry. Briefly, the transfected cells were grown
in 24 well plates for 48 h before harvesting. Cells were
rinsed with PBS and then fixed with 70% ice-cold ethanol
for 30 min. Following two washes with 0.1% foetal serum
albumin in PBS, the cells were suspended in 1 ml 0.1% FBS
containing 10 ll RNase solution (10 mg/ml, DNAse free;
Sigma) and 50 ll propidium iodide solution (1 mg/ml;
Sigma) for 20 min before being analysed on a Beckman
Coulter flow cytometer (Beckman Coulter, Brea, CA, USA).
A minimum of 3 9 104 events were captured, and the data
were analysed by of Weasel software version 2.7 (Walter
and Elisa Hall Institute in Australia). This assay was per-
formed in triplicate on three separate occasions.
Cell migration
Transwell cell migration was measured using a Boyden
chamber containing a polycarbonate filter with an 8 lm
pore size (Costar). Cells were serum starved for synchroniza-
tion, and 5 9 104 cells were seeded in the top chamber in
medium containing 10% foetal calf serum. The lower cham-
ber contained medium which was enriched with 20% foetal
calf serum. Migration across the membrane was assessed
after 48 h by fixing the cells attached to the bottom surface
in 10% methanol for 30 min. These were then stained for
30 min with methylene blue, and the stained cells manually
counted.
Statistical analysis
Statistical analysis was performed using the GraphPad-Prism
program (GraphPad Software Inc., La Jolla, CA, USA). An
unpaired t-test was used to evaluate data derived from the
studies of proliferation, apoptosis and cell motility. A Fish-
er’s exact test was used to test for the association between
the expression of nuclear STAT3 and nuclear b-catenin. All
tests were two tailed, and a P-value of <0.05 was taken as
statistically significant.
Results
STAT3 is a positive regulator of b-catenin protein
Given the mixed published data regarding the nature of the
biochemical interaction of STAT3 and b-catenin, we first
sought to ascertain whether STAT3 and b-catenin were able
to regulate each other. Initially, STAT3 and b-catenin were
knocked down individually in six different CRC cell lines
that is SW620, HT55, SW837, SW480, SW1222 and
SW948, and the effect on protein levels was tested. There
was some variation in the level of protein knock-down
between cell lines which reflects the variation in transfec-
tion efficiency. However, there was robust knock-down of
both proteins with the siRNAs used. In every cell line,
when b-catenin was knocked down, there was no associated
change in the level of STAT3 protein. In contrast, when
STAT3 was knocked down, this was associated with a
marked reduction in the level of b-catenin protein (Fig-
ure 1). We extended our study by knocking down STAT3
only in a further three cell lines that is HT29, C106 and
HCT116 and, our observations were identical (Figure 1b).
As there was no effect on STAT3 levels by b-catenin, the
experiments of knock-down of b-catenin were repeated. As
‘off target’ effects are a classical confounder with gene
knock-down, we knocked down STAT3 using a different
siRNA duplex in three cell lines (i.e. HCT116, HT29 and
SW620) and observed the same effect on b-catenin protein
(Figure S1). As an alternative method to inhibiting Wnt sig-
nalling, we transfected HT29 and HCT116 with DN-TCF4
expression constructs. Forced expression of DN-TCF4
caused a reduction in c-Myc protein (a well-described target
of Wnt signalling) but had no effect on STAT3 levels
(Figure 1c). Thus, our data from a total of nine cell lines
suggest that STAT3 regulates b-catenin levels but not vice
versa.
The immunohistochemical expression of STAT3 and
b-catenin was tested in a small series of primary CRCs.
Staining for b-catenin was seen in all compartments (i.e.
membranous, cytoplasmic and nuclear), whilst STAT3 stain-
ing was seen only in the cytoplasm and nuclei. The mean
score for all assessable cores from each individual case was
used in analysis. For analysis of cytoplasmic staining (of
both proteins), the median score was used as a cut-off point
to dichotomize into ‘positive’ and ‘negative’. For nuclear
staining for STAT3, the median score was used as the cut-
off whilst, for b-catenin, any nuclear staining was scored as
positive. There was a positive association between nuclear
STAT3 expression and nuclear b-catenin expression
(P = 0.022, Table 1, Figures 2 and S2).
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STAT3 alters b-catenin protein through transcriptional
regulation
Changes in b-catenin protein can occur either through
altered protein stability or through altered transcription. To
explore the mechanism of STAT3 mediated regulation of b-
catenin, we knocked down STAT3 in SW620 and exposed
the cells to a proteasome inhibitor. This did not prevent the
reduction in the level of b-catenin suggesting that inhibition
of proteasome-mediated degradation was not the mechanism
through which STAT3 regulated b-catenin (Figure 3a).
The functional activity of the proteasome inhibitor was
Table 1 The results of the immunostaining for STAT3 and b-
catenin in a series of 44 primary colorectal tumours. A
significant positive association (P = 0.022) was found between
nuclear expression of these two proteins
STAT3 + STAT3 Total
b-catenin + 10 8 18
b-catenin  5 21 26
Total 15 29 44
Figure 2 Immunohistochemical expression of b-catenin and
STAT3. The staining for b-catenin (left panel) was seen in
membranous, cytoplasmic and nuclear compartments. The
expression of STAT3 was in the cytoplasm and the nucleus.
There was a significant association between nuclear expression
of b-catenin (arrow) and STAT3 (double arrow). High-power
inserts shown in the corners for both proteins.
(a)
(b) (c)
Figure 1 Western blot data showing
that knock-down of STAT3 results in
downregulation of b-catenin but not
vice versa. (a) This was a reproducible
effect seen in six different colorectal
cancer cell lines. (b) This shows the
effect of STAT3 knock-down, when
tested in a further three colorectal
cancer cell lines, was a reduction in b-
catenin levels. (c) shows that forced
expression of dominant-negative TCF4
(DN-TCF4) caused downregulation of
c-Myc but had no effect on STAT3
when compared to empty vector (EV).
(a)
(b) (c)
Figure 3 Regulation of b-catenin by STAT3 is probably at the
transcriptional level: (a) shows that exposure of SW620 to the
proteasome inhibitor (PI) Z-Leu-Leu-Phe-CHO did not prevent
the downregulation of b-catenin following STAT3 knock-down.
The cell line RKO was used to confirm the efficacy of
proteasome inhibition as exposure to PI resulted in the
appearance of a visible band for b-catenin. +PI indicates cells
were exposed to PI and –PI indicates controls exposed to
DMSO carrier. (b) shows that knock-down of STAT3 resulted
in a downregulation of b-catenin mRNA (data shown as
relative expression compared to control siRNA). (c)
demonstrates stimulation of cells with IL-6 (as an alternative
method of activating STAT3) resulted in upregulation of both
STAT3 mRNA and of b-catenin mRNA (data shown as relative
expression compared to control vehicle).
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confirmed in RKO; these cells do not usually have detectable
b-catenin protein but, on exposure to the proteasomal inhib-
itor, a b-catenin band was visible on Western blot.
To test whether STAT3 altered b-catenin transcription,
we measured b-catenin mRNA levels in four cell lines fol-
lowing STAT3 knock-down. In all four cell lines, a fall in
STAT3 levels was accompanied by a fall in b-catenin mRNA
levels (Figure 3b). To further investigate this, we tested the
effect of IL-6 stimulation of SW620. Stimulation with IL-6
is known to activate STAT3 signalling and induce STAT3
expression(Brocke-Heidrich et al. 2004). Our data showed
that IL-6 stimulation of SW620 resulted in upregulation of
both STAT3 and b-catenin mRNA levels (Figure 3c,
P < 0.001 and P < 0.01 respectively).
STAT3 and b-catenin have a complex biological
interaction
Having shown that STAT3 can regulate b-catenin, we next
sought to ascertain the biological significance of this interac-
tion. STAT3 and b-catenin were knocked down individually
and in combination in SW620 to produce four different con-
ditions that is control cells exposed to luciferase siRNA
(SW620control), STAT3 knock-down only (SW620STAT3-), b-
catenin knock-down only (SW620bcat) and knock-down of
both STAT3 and b-catenin (SW620STAT3/b-cat). The effect
of each of these conditions was tested in a variety of func-
tional assays.
Evaluation of cell numbers over 3 days showed that, com-
pared to controls, each knock-down condition resulted in a
fall in cell number (Figure 4a). STAT3 knock-down alone
caused a reduction in cell number by 30% (SW620STAT3
vs. SW620control, P < 0.001), and b-catenin knock-down
alone only caused a reduction in cell number by 56%
(SW620bcat vs. SW620control, P < 0.001). However, com-
bined knock-down caused a reduction in cell number of
45% which was significantly less than that caused by b-cate-
nin knock-down alone (SW620STAT3/b-cat vs. SW620bcat,
P < 0.01). These findings were reflected to some degree
(albeit without a statistically significant effect) when apopto-
tic cells were evaluated. Numerically, the percentage of
apoptotic cells was SW620control = 2%, SW620STAT3
= 5.4%, SW620bcat = 4.4% and SW620STAT3/b-cat =
5.7% (Figure 4b).
To further investigate the unexpected effects of gene
knock-down on cell number, each of the four conditions
underwent cell cycle analysis by flow cytometry (Figure 4c).
STAT3 knock-down resulted in a greater number of cells
in G1 compared to control cells (SW620STAT3 vs.
SW620control, 50% vs. 46% respectively). As anticipated,
b-catenin knock-down alone resulted in a greater proportion
of cells in G1 (SW620bcat = 56%) but this was greater than
(a)
(b) (c)
(d)
Figure 4 STAT3 and b-catenin interact
in a complex manner. (a) shows that
individual knock-down of both STAT3
and b-catenin (SW620STAT3 and
SW620bcat respectively) results in
inhibition of cell proliferation when
compared with controls (SW620control).
b-catenin has a more marked effect
although combined knock-down
(SW620STAT3/b-cat) results in a lesser
effect than knock-down of b-catenin
alone (P < 0.01). The right hand panel
confirms knock-down of STAT3 and b-
catenin. (b) shows that there was no
difference in the percentage of
apoptotic cells. (c) demonstrates flow
cytometry analysis of SW620 following
knock-down of STAT3 and b-catenin.
This shows that in all conditions, there
are changes in the proportion of cells in
G1 phase and that delayed progression
through G1 may be the partial loss of
b-catenin function that is exerted by
STAT3. The numbers in the boxes
represent the percentage of cells in each
phase of the cell cycle. (d) STAT3 and
b-catenin both inhibit cell motility but
there is no notable interaction when
they are knocked down in combination
compared to individual knock-down.
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the combined knock-down (SW620STAT3/b-cat = 52% in
G1). In all knock-down conditions, the increase in the cells
in G1 phase was accompanied by equivalent reduction in
the percentage of the cells in S phase with relatively little
change in G2.
As both STAT3 and b-catenin can influence cell motility,
we tested their interaction on cell motility using the tran-
swell assay. In each condition (SW620STAT3, SW620bcat
and SW620STAT3/b-cat), there was a significant reduction
in cell motility compared to the control (P < 0.001 for each,
Figure 4d). There was some variation between each of the
conditions, but this was not statistically significant.
Discussion
In the colon, activation of the Wnt signalling pathway is
usually an ‘early’ event involved in tumour initiation, whilst
activation of STAT3 signalling is considered a ‘late’ event
involved in tumour invasion and metastasis. However, there
is a degree of functional redundancy in these pathways, and
it is likely that they will interact with each other in some
way. Our data show that, in contrast to studies conducted
in oesophageal cancer (Yan et al. 2008) and anaplastic large
cell lymphoma (Anand et al. 2010), b-catenin does not influ-
ence levels of STAT3 protein in CRC cell lines. However, in
experiments conducted in nine different CRC cell lines and
using two different siRNA duplexes, we were able to dem-
onstrate that knock-down of STAT3 was associated with a
reduction in the level of b-catenin protein. This suggests that
STAT3 is a positive regulator of b-catenin and is supported
by our analysis of primary tumours showing a positive asso-
ciation between nuclear b-catenin and nuclear STAT3
expression. Our data run contrary to those of Kawada et al.
(Kawada et al. 2006) who, in the CRC cell line SW480,
were not able to demonstrate a change in b-catenin protein
following inhibition with dominant-negative STAT3. Kaw-
ada et al. claimed that the effect of STAT3 was to promote
nuclear localization of b-catenin protein (with consequent
transcriptional activation of targets) but they found no effect
of STAT3 on E-cadherin/b-catenin interaction at the cell
membrane. These findings are directly contradicted by Rivat
et al. (2004) who found that STAT3 had no effect on either
nuclear localization or transcriptional activity of b-catenin
but that a dominant-negative STAT3 caused uncoupling of
the membranous E-cadherin-b-catenin complex. Although it
is not stated, the images shown in Rivat’s paper are highly
suggestive of a reduction in total of b-catenin protein level.
Thus our data, taken together with those seen in Rivat’s
paper, would suggest that STAT3 is a positive regulator of
b-catenin protein.
We sought to ascertain the mechanism by which STAT3
could alter b-catenin protein levels. We found that knock-
down of STAT3 was associated with a fall in b-catenin
mRNA levels and that an increase in b-catenin mRNA levels
was observed following stimulation of cells with IL-6 (a
known activator of STAT3). The fall in b-catenin protein
level following STAT3 knock-down could not, however, be
prevented by a proteasome inhibitor. This would suggest
that b-catenin is transcriptionally regulated by STAT3 and is
consistent with studies in breast cancer showing direct bind-
ing of STAT3 to the b-catenin promoter (Armanious et al.
2010).
We next investigated the biological interaction between
the STAT3 and Wnt signalling pathways. Co-operation of
b-catenin with other oncogenes is well described (Janssen
et al. 2006; Mologni et al. 2010) although it is particularly
interesting in this case as we have shown that STAT3 signal-
ling can alter levels of b-catenin protein. We knocked down
STAT3 and b-catenin protein individually and in combina-
tion. We found that, in agreement with Kawada et al., inhi-
bition of STAT3 resulted in a reduction in cell numbers.
Knock-down of b-catenin resulted in a more pronounced
reduction of cell numbers. However, combined knock-down
resulted in a significantly less pronounced reduction than
knock-down of b-catenin alone (P < 0.01). This would sug-
gest that, either directly or indirectly, STAT3 has an inhibi-
tory effect on b-catenin-driven proliferative activity. Such an
effect has also been described in mouse models where loss
of STAT3 promoted proliferation in germline Apc mutant
Min mice (Musteanu et al. 2009). It is generally regarded
that, for optimal activity, b-catenin protein levels must oper-
ate at ‘just right’ levels (Albuquerque et al. 2002). We
would speculate that increases in b-catenin caused by
STAT3 could take protein levels beyond the optimal range
and thereby compromise b-catenin function.
Evaluation of apoptosis (through uptake of trypan blue)
showed no difference between b-catenin and combine
STAT3/b-catenin knock-down. However, cell cycle analysis
raised the possibility that the inhibitory effect of STAT3 may
be on progress through G1. Evaluation of cell motility
showed more or less an equivalence between all three knock-
down conditions with no evidence of interaction. This
contradicts the data of Rivat et al. who found that dominant-
negative STAT3 promoted invasive properties in cells.
Our data suggest that interaction between STAT3 and
b-catenin results in a partial inhibition of cell proliferation
but does not affect cell motility. It is highly likely that STAT3
will give a selective advantage, and as STAT3 activation is a
late event, one can conjecture that a slight loss of prolifera-
tive activity is an acceptable cost for acquisition of other fea-
tures which may be more relevant to the tumour at that
stage. The biological interaction between STAT3 and b-cate-
nin is obviously complex, but it raises the intriguing possibil-
ity that tumours in which both these pathways are activated
may be biologically different to tumours in which in only of
these pathways is activated. Such differences could be
exploited to develop further personalized medicine for CRC.
In summary, we have investigated the biochemical and
biological interaction of the Wnt and STAT3 signalling
pathways in CRC. We have shown that STAT3 can regulate
b-catenin but not vice versa. Furthermore, the biological
interaction between these two pathways is complex, and it
is possible that, in advanced CRCs, STAT3 is partially
inhibiting b-catenin-driven proliferation.
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. This shows the effect of STAT3 knock-down
with a different siRNA duplex (denoted as STAT3(ii)).
There was a reduction in b-catenin levels when tested in
three colorectal cancer cell lines.
Table S1. This shows the sequences for the siRNA
duplexes used in the study.
Table S2. This shows the sequences for the primers used
for PCR in the study.
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